US 11,898,147 B2
CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
Tsung-Hsien Chuang, Zhunan Township (TW); Jen-Chih Tseng, Zhunan Township (TW); Jing-Xing Yang, Zhunan Township (TW); and Yi-Ling Liu, Zhunan Township (TW)
Assigned to NATIONAL HEALTH RESEARCH INSTITUTES, Zhunan Town (TW)
Filed by National Health Research Institutes, Zhunan Township (TW)
Filed on Sep. 6, 2021, as Appl. No. 17/467,390.
Prior Publication US 2023/0075652 A1, Mar. 9, 2023
Int. Cl. C07H 21/02 (2006.01); C12N 15/117 (2010.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 31/711 (2006.01)
CPC C12N 15/117 (2013.01) [A61K 31/711 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 3 Claims
 
1. A pharmaceutical composition for treating cancer, comprising an immune checkpoint blockade and an adjuvant composition; wherein the adjuvant composition comprises at least one CpG-oligodeoxynucleotide; wherein the CpG-oligodeoxynucleotide is CpG-2722 (SEQ ID NO:5), the immune checkpoint blockade is an anti-PD1 antibody.